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Abstract Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food
and Drug Administration for prophylaxis of venous thromboembolism in adult patients
hospitalized for an acute illness at risk for thromboembolic complications. Assessment
of the anti-coagulant effect of betrixaban may be useful in some situations. Also,
clinicians need to know how routine coagulation assays are inﬂuenced.
Objective The aim of this study is to determine which coagulation assay(s) should be
used to assess the impact of betrixaban on haemostasis and provide laboratory
guidance for their interpretation.
Materials and Methods Betrixaban was spiked at ﬁnal concentrations ranging from 0
to 250 ng/mL in platelet-poor plasma. Different reagents from several manufacturers
were tested and the impact of betrixaban on pro-thrombin time (PT), activated partial
thromboplastin time (aPTT), dilute Russel viper venom time (dRVV-T), chromogenic
anti-Xa assays, thrombin generation assay (TGA), and a large panel of haemostasis
diagnostic tests has been assessed.
Results A concentration-dependent prolongation of aPTT, PT and dRVV-T is observed.
The sensitivity mainly depends on the reagent. Chromogenic anti-Xa assays show high
sensitivity depending on the reagent and/or the methodology. These assays applicable
for other direct factor Xa inhibitors have to be adapted to obtain a relevant range of
measurement. TGA may also be attractive to assess the anti-coagulant activity of
betrixaban.
Conclusion Adapted chromogenic anti-Xa assays are the most appropriate assays to
estimate the concentration of betrixaban. Betrixaban signiﬁcantly affects several
haemostasis diagnostic tests and this needs to be taken into consideration when
requesting and interpreting such tests.
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Coagulation and Fibrinolysis
Introduction
Betrixaban, a novel direct oral factor Xa (FXa) inhibitor
developed by Portola Pharmaceuticals Inc., has received its
market authorization under the brand name of BevyxXa on
the 23rd of June 2017 in the United States for the prophylaxis
of venous thromboembolisms (VTE) in adult patients.1 The
approval was based on the data from the Acute Medically Ill
Prevention with Extended Duration Betrixaban Study, a
randomized, double-blind, multi-national clinical trial com-
paring extended duration betrixaban to short duration enox-
aparin in the prevention of VTE in an acutely medically ill
hospitalized population with risk factors for VTE.2–6 It has
been developed to have a low renal clearance (< 7% of
administered dose), a minimal hepatic metabolism (< 1%)
and a long half-life (37 hours).7 Although direct oral anti-
coagulants (DOACs) do not require routine monitoring, the
assessment of their effect on coagulation may be useful in
some clinical situations (e.g., detection of drug accumulation
in acute renal or hepatic failure; planning the timing of
urgent invasive procedure; recurrence of stroke or bleedings,
etc.).3,8 In this study, spiked plasma has been used to realize
calibration curve. This technique has already been used in
the past for the assessment of other DOACs.9–12 It has been
found that we can reliably apply these results in real-life
samples. Indeed, some studies revealed similarities between
in vitro and ex vivo data for rivaroxaban.13–15
The primary aim of this study is to assess and compare the
performance of routinely used andmore speciﬁc coagulation
assays tomeasure the anti-coagulant effect of betrixaban and
estimate its plasma concentration. In addition, good labora-
tory recommendations for the interpretation of haemostasis
diagnostic tests that may be affected by betrixaban will be
provided.
Materials and Methods
Betrixabanwas spiked at increasing concentrations in pooled
citrated normal human platelet-poor plasma (PPP). The
tested concentrations cover the on-therapy range
(from  9 ng/mL at Ctrough to  122 ng/mL at Cmax for the
40 and 120 mg once daily doses, respectively, according to
the clinical pharmacology and biopharmaceutics reviews of
the Center for Drug Evaluation and Research).16
Testing Solutions of Betrixaban
Betrixaban (molecular weight: 451.90 g/mol; purity
¼ 92.35%) was obtained from ChemScene (Monmouth
Junction, New Jersey, United States). A stock solution at
1.0 mg/mL in dimethyl sulfoxide (DMSO) was obtained and
intermediate solutions at 100, 300, 500, 1,000, 1,500 and
2,500 ng/mL diluted in phosphate-buffered saline without
Ca2þ and Mg2þ were prepared. Working solutions of 10, 30,
50, 100, 150 and 250 ng/mL of betrixaban were obtained by
mixing these stock solutions with normal pooled plasma
(NPP) (1:9 v/v). According to purity, these concentrations
represented 9.2, 27.7, 46.2, 92.4, 138.5 and 230.9 ng/mL
of active betrixaban, respectively, in plasma. The DMSO
concentration in plasma was  0.05% (v/v) which did not
inﬂuence the coagulation.17
Preparation of Platelet-Poor Plasma
Fifty-six individuals were included in the study. The exclu-
sion criteria were thrombotic and/or haemorrhagic events,
anti-platelet and/or anti-coagulant medication, hormonal
therapy, pregnancy and uptake of drugs potentially affecting
the platelet and/or coagulation factor functions during the
2 weeks prior to the blood drawn. The study protocol is in
accordancewith the Declaration of Helsinki. Bloodwas taken
by venipuncture in the antecubital vein and collected into
0.109 M sodium citrate (9:1 v/v) tubes (Venosafe, Terumo,
Belgium) using a 21-gauge needle (Terumo). The PPP was
obtained from the supernatant fraction of blood tubes after a
double centrifugation for 15 minutes at 1,500  g at room
temperature. Immediately after centrifugation, PPP from the
56 donors were brought together to obtain the NPP which
was frozen at –80°C without any delay. Frozen NPP samples
were thawed and heated to 37°C for 5 minutes just before
experiment. All tests were performed within 4 hours after
thawing.
Routinely Used and Speciﬁc Coagulation Assays
A summary of the different assays and their reagents per-
formed in this study is provided in►Table 1. Several reagents
have been used for some tests. All tests were performed in
accordance with the recommendations of the manufacturers,
or otherwise this is speciﬁed in the sections below. Depending
on the test and reagent, evaluationswere performed on a STA-
R Evolution (Diagnostica Stago, Asnières-sur-Seine, France), a
STA-R Max (Diagnostica Stago), an ACL-TOP 700 (Instrumen-
tation Laboratory, Lexington, Kentucky, United States) or an
Ascent Fluoroscan (Thermo Fisher Scientiﬁc, Waltham, Mas-
sachusetts, United States) using the calibrated automated
thrombogramsoftware (CAT, ThrombinoscopeBV,Maastricht,
The Netherlands) (►Table 1).
Pharmacodynamics Assays
To evaluate the anti-coagulant effect of betrixaban, pro-
thrombin time (PT), activated partial thromboplastin time
(aPTT), dilute Russell viper venom time (dRVV-T), chromo-
genic anti-Xa assays and the thrombin generation assay
(TGA) were assessed. PT, aPTT, dRVV-T and TGA were per-
formed in accordance with the recommendations of the
manufacturer.
For all chromogenic anti-Xa assays, the results were
collected as optical densitometry (OD)/min by using several
reagents and methodologies (►Table 1).
For STA-Liquid Anti-Xa, DiXaI and Technochrom Anti-Xa
assays, the methodologies provided by the manufacturer for
the assessment of rivaroxaban were used but the tests were
not calibrated with rivaroxaban calibrators and results were
reported as OD/min.
For the following anti-Xa chromogenic assays, an adapted
method was proposed with the aim of increasing the
dynamic range of quantitation. For Biophen Heparin LRT,
50 µL of spiked NPP diluted at 1:10 or 1:2 in physiological
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Table 1 Overview of the different assays performed in this study
Coagulation assay Reagent Manufacturer Method Coagulation analyser
(manufacturer)
Pro-thrombin time TriniCLOT PT Excel S Tcoag, Bray, Ireland Chronometric STA-R Evolution
(Diagnostica Stago)TriniCLOT PT Excel
TriniCLOT PT HTF
STA-NeoplastineR Diagnostica Stago,
Asnieres, FranceSTA-Neoplastine CIþ
Dade Innovin Siemens Healthcare
Diagnostics, Deerﬁeld,
Illinois, United States
RecombiPlasTin 2G Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Activated partial
thromboplastin time
STA-C.K.Prest Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)STA-Cephascreen
STA-PTT Automate
Actin FS Siemens Healthcare
Diagnostics, Deerﬁeld,
Illinois, United States
SynthASil Instrumentation
Laboratory, Lexington,
Kentucky, United
States
SynthAfax ACL-TOP
(Instrumentation
Laboratory)
Thrombin time STA-Thrombin Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)
Lupus anti-coagulant STA-Staclot DRVV
Screen
Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)
STA-Staclot DRVV
Conﬁrm
Reptilase time STA-Reptilase Diagnostica Stago,
Asnieres, France
Chronometric STA-R Evolution
(Diagnostica Stago)
Anti-thrombin STA-Stachrom ATIII Diagnostica Stago,
Asnieres, France
Chromogenic
(thrombin-based)
STA-R Evolution
(Diagnostica Stago)
HemosIL Liquid
Antithrombin
Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chromogenic
(FXa-based)
ACL-TOP
(Instrumentation
Laboratory)
Chromogenic anti-Xa
assays
Biophen Direct Factor
Xa Inhibitors
Hyphen BioMed,
Neuville-sur-Oise,
France
Chromogenic STA-R Evolution
(Diagnostica Stago)
Biophen Heparin LRT
STA-Liquid Anti-Xa Diagnostica Stago,
Asnieres, France
Technochrom Anti-Xa Technoclone, Vienna,
Austria
HemosIL Liquid
Heparin
Instrumentation
Laboratory, Lexington,
Kentucky, United
States
ACL-TOP
(Instrumentation
Laboratory)
Thrombin generation
assay
PPP-Reagent Low Thrombinoscope BV,
Maastricht, The
Nederland’s
Fluorimetric Calibrated Automated
Thrombogram
(Thrombinoscope BV)
PPP-Reagent
PPP-Reagent High
(Continued)
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saline were mixed with 125 µL of chromogenic substrate
(SXa-11) and incubated for 240 seconds at 37°C. Then,
125 µL of bovine FXa pre-warmed at 37°C was added. For
HemosIL Liquid Heparin, 200µL of spiked NPP was mixed
with 100 µL of chromogenic substrate (S2732) and incubated
for 180 seconds at 37°C. Thereafter, 75 µL of bovine FXa was
added. For DiXaI, two procedures were used (normal or low).
Brieﬂy, 200 µL of spiked NPP diluted at 1:50 (normal proce-
dure) or 1:15 (low procedure) in Tris-NaCl-ethylenediami-
netetraacetic acid (EDTA) reaction buffer provided by the
manufacturer was mixed with 75 µL of human FXa and
incubated for 120 seconds at 37°C. Then, 75 µL of FXa-
speciﬁc chromogenic substrate (CS11(65)) pre-warmed at
37°C was added. For STA-Liquid anti-Xa, 30 µL of spiked NPP
diluted at 1:4 in physiological saline was mixed with 150 µL
of chromogenic substrate (CBS 02.44) and incubated for
240 seconds at 37°C. Then, 150 µL of bovine FXa pre-warmed
at 37°C was added. Finally, for Technochrom Anti-Xa, 85µL of
spiked NPP diluted 1:15 or 1:5 in Tris-EDTA buffer provided
by themanufacturer wasmixedwith 85 µL of bovine FXa and
incubated for 240 seconds at 37°C. Then, 85 µL of chromo-
genic substrate pre-warmed at 37°Cwas added. All measure-
ments were performed on STA-R Evolution.
Diagnostic Assays
The inﬂuence of betrixaban on the following diagnostic tests
has also been investigated. Thus, in addition to PT, aPTT and
dRVV-T, which could be useful for the assessment of betrix-
aban as described above, Fibrinogen (Fib), clotting factors,
protein C and S and anti-thrombin (AT) measurements,
thrombin time (TT) and reptilase time (RT) have also been
performed. Investigations for lupus anti-coagulant (LA) and
activated protein C resistance were also assessed.
Determination of Lupus Anti-Coagulant: Dilute Russell Viper
Venom Time
The diagnosis of anti-phospholipid syndrome can be done by
the estimation of the percentage of correction obtained with
the dRVV-T: (Screen – Conﬁrm)/Screen)100. The cut-off of
5% of correction is proposed by the British Committee for
Standards in Haematology guidelines for the investigation of
LA (reference ratio is 0.9:1.05).18
Anti-Thrombin Measurement
Antithrombin measurement was performed using the STA-
Stachrom ATIII (Diagnostica Stago), a chromogenic assay
based on the inhibition of bovine FIIa, and the HemosIL
Liquid Antithrombin (Instrumentation Laboratory), a chro-
mogenic assay based on the inhibition of bovine FXa.
Fibrinogen Measurement (Clauss Method and PT-Derived)
For the Clauss method, 150 µL of plasma diluted at 1:20 with
saline solutionwas incubated for 240 seconds. Then, 50 µL of
STA-Liquid Fib (Diagnostica Stago) was added to trigger the
coagulation. For the PT-derivedmethod, 50 µL of plasmawas
mixed with 100 µL of RecombiPlasTin 2G (Instrumentation
Laboratory) to trigger the coagulation.
Thrombin Time
Thrombin time was investigated with the STA-Thrombin
(Diagnostica Stago) according to the recommendations of
the manufacturer.
Table 1 (Continued)
Coagulation assay Reagent Manufacturer Method Coagulation analyser
(manufacturer)
Evaluation of extrinsic
clotting factor levels
RecombiPlasTin 2G Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chronometric STA-R Max
(Diagnostica Stago)
Evaluation of intrinsic
clotting factor levels
STA-C.K.Prest Diagnostica Stago,
Asnieres, France
Chronometric STA-R Max
(Diagnostica Stago)
Fibrinogen Clauss
method
STA-Liquid Fib Diagnostica Stago,
Asnieres, France
Chronometric STA-R Max
(Diagnostica Stago)
Fibrinogen PT-derived RecombiPlasTin 2G Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chronometric ACL-TOP
(Instrumentation
Laboratory)
Protein S Protein S Activity Instrumentation
Laboratory, Lexington,
Kentucky, United
States
Chronometric ACL-TOP
(Instrumentation
Laboratory)
Protein C STA-Stachrom Protein
C
Diagnostica Stago,
Asnieres, France
Chromogenic STA-R Max
(Diagnostica Stago)
Activated protein C
resistance
STA-Staclot APC-R Diagnostica Stago,
Asnieres, France
Chronometric STA-R Max
(Diagnostica Stago)
Abbreviations: PPP, platelet-poor plasma; PT, pro-thrombin time.
Thrombosis and Haemostasis
Betrixaban: A Practical Laboratory Guide Siriez et al.
Reptilase Time
Reptilase time was investigated using STA-Reptilase (Diag-
nostica Stago) according to the recommendations of the
manufacturer.
Protein C Activity Measurement
The activity of protein C was investigated using STA-Sta-
chrom Protein C (Diagnostica Stago) according to the recom-
mendations of the manufacturer.
Protein S Activity Measurement
The activity of protein S was investigated using Protein S
Activity (Instrumentation Laboratory) according to the
recommendations of the manufacturer.
Assessment of Activated Protein C Resistance
The activity of protein C resistance was investigated using
STA-Staclot APC-R (Diagnostica Stago) according to the
recommendations of the manufacturer.
Measurement of Clotting Factors
Intrinsic clotting factors activity (VIII, IX, XI and XII) was
assessed using STA-C.K.Prest (Diagnostica Stago). Fifty
microlitre of spiked NPP diluted at 1:10, 1:20 or 1:40 in
physiological saline was incubated for 240 seconds at 37°C
after adding 50 µL of deﬁcient plasma (Diagnostica Stago)
and 50 µL of STA-C.K.Prest. Coagulation was then triggered
by adding 50 µL of CaCl2 0.025 M. Extrinsic clotting factors
activity (II, V, VII and X) was assessed using RecombiPlasTin
2G. Fiftymicrolitre of spikedNPP diluted at 1:10, 1:20 or 1:40
in physiological salinewas incubated for 240 seconds at 37°C
after adding 50 µL of deﬁcient plasma. Coagulationwas then
triggered by adding 100 µL of RecombiPlasTin 2G. All mea-
surements were performed on a STA-R Max coagulometer.
Statistical Analysis
Statistical analyses and graphics were computed using
GraphPad Prism 5.04 for Windows 7 Professional (GraphPad
Software, La Jolla, California, United States).
To compare the sensitivity of the different clotting assays,
the concentration of betrixaban needed to double the clot-
ting time (2  CT [CT ¼ clotting time]) was used. For chro-
mogenic assays, the sensitivity is deﬁned as the
concentration of betrixaban needed to halve the analytical
parameter (1/2  OD/min [the concentration needed to
halve the change in the OD reported by minute]). For the
CAT, the sensitivity of the different parameters is deﬁned as
follow: Cmax IC50 (the concentration reducing the Cmax of
50%); peak IC50 (the concentration reducing the peakof 50%);
mVRI IC50 (the concentration reducing the mVRI of 50% [the
mean velocity rate index (mVRI) represents the effective rate
of thrombin generation (i.e., the slope) between lag time and
time to peak]); mVRI ¼ Peak/(time to peak – lag time);
2  LT (the concentration needed to double the lag time
[LT]); 2  TTP (the concentration needed to double the time
to peak [TTP]).
Except for clotting factor activities that were run only
once, each test was run in triplicate on the same day. Data on
the graphics represent the mean of triplicates. The repeat-
ability is deﬁned as the mean of the coefﬁcient of variation
(CV) ([standard deviation/mean]100) of the triplicate of
each concentration for each test.
For tests evaluated for the assessment of the pharmaco-
dynamics of betrixaban (i.e., aPTT, PT, chromogenic anti-Xa
assays, dRVV-T and CAT), the limit of detection (LOD) and
quantitation (LOQ) were calculated as follow:
– LOD: [(3standard deviation of Y0)/slope]
– LOQ: [(10standard deviation of Y0)/slope]
where Y0 is the baseline value of the linear regression. For
assays that did not ﬁt a linear response on their entire range of
measurement (i.e., BiophenDirect FactorXa inhibitors [DiXaI];
BiophenHeparin LRT; STA Liquid Anti-Xa; TechnochromAnti-
Xa normal and high; and HemosIL Liquid heparin), the ﬁrst
points of the calibration curve were used to deﬁne a linear
regression. The slopeof this linear regressionwas thenused for
the calculation of the LOD and LOQ.
Results
Pharmacodynamics Assays
Pro-Thrombin Time
A concentration-dependent prolongation of PT was found.
The 2  CT depended on the reagent and ranged from
198 ng/mL (STA-NeoplastineR) to 514 ng/mL (Dade Innovin).
PT may be normal (ratio < 1.2) with on-therapy concentra-
tion of betrixaban depending on the reagent (►Fig. 1;
►Supplementary Fig. S1, online only). The repeatability
was always below 2%. The LOD and LOQ ranged from 5 to
36 ng/mL and from 11 to 107 ng/mL, respectively.
Activated Partial Thromboplastin Time
The aPTT showed a concentration-dependent prolongation
of clotting time. The 2  CT depended on the reagent and
ranged from 257 ng/mL (SynthAfax) to 479 ng/mL (STA C.K.
Prest) (►Fig. 2; ►Supplementary Fig. S2, online only). The
repeatability was always below 2%. The LOD and LOQ ranged
from 16 to 57 ng/mL and from 21 to 152 ng/mL, respectively.
Dilute Russell Viper Venom Time
STA-Staclot-DRVV Screen and Conﬁrm were also prolonged
dose-dependently (►Fig. 3; ►Supplementary Fig. S3, online
only). The 2  CTwas 80 ng/mL for STA-Staclot-DRVV Screen
and 108 ng/mL for STA-Staclot-DRVV Conﬁrm. The repeat-
ability ranged from 0.8% (STA-Staclot-DRVVConﬁrm) to 0.9%
(STA-Staclot-DRVV Screen). The LOD and LOQ were 5 and
17 ng/mL for the DRVV Screen and 6 and 22 ng/mL for DRVV
Conﬁrm, respectively.
Chromogenic Anti-Xa Assays
A concentration-dependent decrease in OD/min was
observed (►Fig. 4; ►Supplementary Fig. S4, online only).
The reactions were ﬁtted by an exponential model. The 1/2
OD/min ranged from 120 ng/mL (Biophen Heparin LRT Low)
to 569 ng/mL (TechnochromAnti-Xa High). The repeatability
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was from 0.6% (Biophen Heparin LRT) to 3.1% (HemosIL
Liquid Heparin). The LOD and LOQ ranged from 1 to
72 ng/mL and from 4 to 185 ng/mL, respectively.
Thrombin Generation Assay
The most inﬂuenced parameters were the peak (Cmax IC50: 8–
28ng/mL)andthemVRI (mVRI IC50: 7–10ng/mL),while thelag
time, the time to peak and the endogenous thrombinpotential
were less affected, as reported in ►Fig. 5. The prolongation/
inhibition of all parameters decreased inversely to the amount
of tissue factor (TF) in the reagent. The CVof the triplicate was
always below 10%. The LOD and LOQ for the peak ranged from
37 to 58 ng/mL and from 122 to 193 ng/mL, respectively. For
Fig. 1 Impact of betrixaban on pro-thrombin time (PT). Betrixaban
showed a concentration-dependent prolongation of the PT. The
relation was linear and the 2 x CT depended on the reagent. The
2  CTranged from 198 ng/mL for STA-NeoplastineR to 514 ng/mL for
Dade Innovin (r2: correlation coefﬁcient; 2  CT: 2  clotting time
expressed in ng/mL; CV: coefﬁcient of variation expressed in per-
centage [%]).
Fig. 3 Impact of betrixaban on the dilute Russell viper venom time
(dRVVT). Betrixaban prolonged the dilute Russell viper venom time
dose-dependently. The relation is curvilinear showing a lower sensi-
tivity at the higher concentrations (from 150 ng/mL). However, the
higher sensitivity at the lower concentrations is interesting since it
provides a low limit of detection and quantitation.
Fig. 2 Impact of betrixaban on activated partial thromboplastin time.
Betrixaban showed a concentration dependent prolongation of the
activated Partial Thromboplastin Time. The relation was curvilinear
and the 2CT depended on the reagent. The 2CT was ranging
from 257ng/mL for SynthAfax® to 479ng/mL for STA®-C.K. Prest®. (r2:
Correlation Coefﬁcient; 2CT: 2 Clotting Time expressed in ng/mL;
CV: Coefﬁcient of variation expressed in percentage [%]; NC; Not
calculated. The plateau does not reach a ratio of 2 for the concen-
trations tested in this study).
Fig. 4 Measurement of betrixaban with chromogenic anti-Xa assays.
There was a concentration-dependent decrease of the OD/min. Tests
with higher baseline OD/min had a wider range of quantitation
compared with those starting at lower OD/min at baseline (r2:
correlation coefﬁcient; 1/2  OD/min: halve in optical density
by minute expressed in ng/mL; CV: coefﬁcient of variation expressed
in percentage [%]). Some tests are not sufﬁciently inﬂuenced with the
current methodologies and need to be adapted.
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the mVRI, the LOD and LOQ ranged from 18 to 27 ng/mL and
from 66 to 88 ng/mL, respectively.
Diagnostic Assays
Determination of Lupus Anti-Coagulant: Dilute Russell
Viper Venom Time
A curvilinear prolongation of % correction was observed
(►Supplementary Fig. S5, online only). The cut-off of 5% of
correction was reached at betrixaban concentration of
38 ng/mL.
Fibrinogen, Anti-Thrombin, Protein C, ThrombinTime and
Reptilase Time Measurements
These assays were not inﬂuenced by the presence of betrix-
aban at the concentration tested in this study.
Protein S Measurement
Protein S measurement showed a concentration-dependent
linear prolongation (►Supplementary Fig. S6, online only).
The 2  CT was 253 ng/mL and the repeatability was 1.2%.
The LOD and LOQ were 12 to 22 ng/mL, respectively.
Assessment of Activated Protein C Resistance
Protein C resistance assessment showed a concentration-
dependent curvilinear prolongation (►Supplementary
Fig. S7, online only). The repeatability was 1.1%. The LOD
and LOQ were 7 and 15 ng/mL, respectively.
Clotting Factor Measurement
For factors of the intrinsic pathway (FVIII, FIX, FXI and FXII), the
aPTT-basedclottingmethodshowedameandecreaseof  7%at
10 ng/mL of betrixaban, 19% at 50 ng/mL and 42% at 150 ng/mL
with a diluted sample (1:10). The impactwasmore pronounced
for FXI and FVIII as presented in ►Supplementary Table S1
(onlineonly) and►Supplementary Fig. S8 (onlineonly). For FV,
FVII and FX, a mean decrease of 2% at 10 ng/mL of betrixaban,
10% at 50 ng/mL and 24% at 150 ng/mL was observed with a
dilution of 1:10, while pro-thrombin measurement seemed to
be less affected (maximal decrease of 6% at 150 ng/mL with a
dilution of 1:40) (►Supplementary Table S1, online only, and
►Supplementary Fig. S8, online only). A correction of the
impact of betrixaban was observed with higher dilution (i.e.,
1:20 or 1:40).
Discussion
The aim of this study was to investigate the impact of
betrixaban on a series of routine ormore speciﬁc coagulation
tests to provide good recommendations to estimate the anti-
coagulant effect of the treatment as well as to correctly
interpret the results of diagnostic tests, whichmay be altered
by the presence of this novel direct FXa inhibitor. Several
reagents andmethodologies have been assessed onNPP from
healthy volunteers spiked with betrixaban to provide good
laboratory practice at the laboratory level.
Some limitations of our study have to be recognized. One
limitation of this study is the use of NPP spiked with
Fig. 5 Impact of betrixaban on calibrated automated thrombogram
(CAT). The most inﬂuenced CAT parameters are the peak and the
mean velocity rate index. There is an inter-reagent variability. Thanks
to their low IC50 for the peak and the mVRI, the better resolution and
their large range of application, platelet-poor plasma (PPP)-Reagent
Low, PPP-Reagent and PPP-Reagent High seemed to be the best
reagents to monitor patients on betrixaban (ETP: endogenous
thrombin potential; IC50: half-maximum inhibitory concentration; LT:
lag time; mVRI: mean velocity rate index; TTP: time to peak). mVRI
was deﬁned as: (Peak)/(Time to peak – Lag time).
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betrixaban. This technique has already been used in the past
for the assessment of other DOACs.9–12 It has been found that
we can reliably apply these results in real-life samples.
Indeed, some studies revealed similarities between in vitro
and ex vivo data for rivaroxaban13–15 and this might be
applicable to betrixaban. Further investigations are required
to conﬁrm these data and evaluate the inter-individual
variability in patients treated with betrixaban.
Routinely Used and Speciﬁc Coagulation Assays:
Advantages and Drawbacks
Routine Tests and Derivation of Speciﬁc Assays Acting on
Factor X
Prothrombin time is broadly used to assess the impact of
DOAC therapy but failed to be recommended as the reference
assay for the assessment of direct FXa inhibitors.19According
to our results, PT is not sensitive enough to estimate betrix-
aban plasma concentrations and, depending on the reagent,
may be normal in presence of concentrations observed in the
on-therapy range. Thus, in addition to the biological and pre-
analytical variables that may affect PT, this inter-reagent
variability prevents valid recommendations of cut-offs
in seconds associated with a bleeding risk applicable to all
reagents. In addition, drugs or haematologic abnormalities
affecting at least one factor assessed by PT could also inter-
fere and bias the conclusions.10,20 Deﬁnitively, PT should not
be recommended to estimate plasma concentration of
betrixaban. This result corroborates previous investigations
about PT and DOACs (rivaroxaban, apixaban, dabigatran and
edoxaban).9,10,19,21
For aPTT, a concentration-dependent prolongation is
shown in presence of increasing doses of betrixaban. This
routine test is not sensitive enough to estimate betrixaban
plasma concentrations and depending on the reagent used, it
may not be inﬂuenced at concentrations observed in the on-
therapy range. aPTT should not be recommended to estimate
plasma concentration of betrixaban. The dependence of the
reagent has previously been investigated and observed for
dabigatran, apixaban, rivaroxaban and edoxaban.8,22,23
The dRVV-T is usually used for the assessment of anti-
phospholipid syndrome.24Previous studies suggested that this
test could be used for the evaluation of all DOACs but it has
never been assessed on betrixaban. The concentration-depen-
dent prolongation of dRVV-T showed a curvilinear correlation,
suggesting a plateauing effect at higher concentrations.25 The
reagents used present a high sensitivity to ensure a reliable
assessment of drug effect. These results are consistent with
results obtained with others direct FXa inhibitors.19,26,27
In previous studies, routine tests have already been
assessed to estimate the impact of DOACs in real-life sam-
ples9 and it has been demonstrated that PT and aPTTmay not
be adequate to estimate drug levels.19,28 For a particular
chronometric assay, the between-reagent variability could
be explained by the differences in the composition of the
reagent. The source of phospholipids (e.g., phosphatidylser-
ine, phosphatidylethanolamine or phosphatidylcholine),
their proportion in the reagent, as well as other factors
such as the ionic force, the pH, the source of TF (for PT) or
the activator (for aPTT) could provide some explanations.
Furthermore, Smith et al demonstrated that traces of acti-
vated FVII could modulate thromboplastin sensitivity to FV,
FVII, FX and pro-thrombin.29,30
Chromogenic anti-Xa assays have already been described
as accurate assays for the measurement of plasmatic drug
level of direct FXa inhibitors.8,10,22,31,32 The different chro-
mogenic assays available in the market used in this study
showed linear or exponential relations depending on the
reagent and the methodology applied. Compared with other
chromogenic anti-Xa assays, Biophen DiXaI is speciﬁc for
direct FXa inhibitors such as betrixaban.8,33 Namely, thanks
to its Tris/EDTA/NaCl buffer at pH ¼ 7.85, this assay is
insensitive to the presence of AT-dependent FXa inhibitors.34
However, it has been reported that the low procedure of the
Biophen DiXaI may not warrant the speciﬁcity for direct FXa
inhibitors anymore. This may be due to an insufﬁcient
dilution of the plasma sample in the speciﬁc buffer35 (see
also the “Materials and Methods” section). As the low
procedure seems to be more recommended for the assess-
ment of betrixaban, thismay be a problem in case of bridging
therapy. Importantly and according to the dynamic range of
quantitation of the current chromogenic assays, further
investigations should be done to assess the on-therapy
concentration of betrixaban (►Table 2). The different sensi-
tivity observed with the different chromogenic anti-Xa
assays could be explained by differences in chromogenic
substrate, origin of FXa, as well as by the ratio between the
substrate and the FXa brought into the test.36 The ionic force
and the pH of the buffer solution could also be parameters
that can impact the sensitivity of a particular assay.9 Thus,
betrixaban does not respond similarly to chromogenic anti-
Xa assays than do other direct FXa inhibitors. This is due to
the low plasma concentrations observed in the clinical
development, which require tests sensitive at very low
equivalent plasma levels. Also, a different afﬁnity for FXa
compared with other direct FXa inhibitors is possible, as
already observed between apixaban and rivaroxaban.37
Development of speciﬁc methodologies for betrixaban are
thus required, which may be a barrier to the development of
a universal chromogenic anti-Xa assay applicable to DOACs
and heparins.
The CAT gives more information than traditional coagula-
tion assays.38 By its mode of action, betrixaban mainly acts
on the ampliﬁcation phase of the thrombin generation,
affecting mostly the peak and the mVRI. The sensitivity
towards the lag time and the time to peak depends on the
quantity of TF in the reagent. So, the sensitivity towards the
lag time decreaseswith the amount of TF in the reagent since
all reagent tested in this study contain 4 µM of phospholi-
pids. Inversely, the sensitivity towards the time to peak
increases with the amount of TF in the reagent.
Impact of betrixaban on Haemostasis Diagnosis
Assays
As other anti-coagulant drugs, betrixaban may affect the
results of a series of coagulation assays routinely used in case
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of thrombophilia or in the exploration of a haemorrhagic
event. Our results on routine tests (i.e., PT and aPTT) suggest
that sensitivity depends on the reagents used for a particular
assay and, thus, there is a need for clinicians to discuss with
the laboratory to knowwhether these tests are inﬂuenced by
betrixaban to avoid misdiagnosis and useless investigations
(►Table 3).
The ATmeasurement using FXa-based or FIIa-based chro-
mogenic assays are not inﬂuenced by betrixaban. Thus, in
patients treated with betrixaban, thrombin-based or FXa-
based chromogenic assays might be used for the assessment
of AT rate. Clinically relevant concentration of betrixaban
may interfere with the measurement of clotting factors.
However, the relation is not linear, as suggested by the
plateauing effect observed with the aPTT or the dRVV-T.
Dilution of the sample tends to reduce the drop of clotting
factors between baseline and high betrixaban concentration,
as already stated for rivaroxaban, apixaban and edoxa-
ban.9,10,39 As mentioned, the dRVV-T is affected by betrix-
aban, and prolongation of the clotting time may depend on
the concentration, the composition and the concentration of
phospholipids (i.e., as demonstrated in this study, the screen-
ing reagent is more sensitive than the conﬁrm).25,29,30
Therefore, dRVV-T should be avoided for the assessment of
LA in patients treated with betrixaban since the ratio
between the screen and the conﬁrmwill be increased giving
possible false-positive results. This has already been
reported with other direct FXa inhibitors.40 To avoid such
results, manufacturers aim to develop methods to remove
DOAC from the plasma sample, without affecting the char-
acteristics of the clotting abnormalities.8,41 Another possi-
bility to reduce the impact of betrixaban is to increase the
dilution of the sample (i.e., at least 1:40). Measurement of
protein S does not seem to be inﬂuenced until 10 ng/mL of
betrixaban but show an over-estimation of approximately
10% at 30 ng/mL.
In clinical routine practice, it is preferable to use assays
that do not involve FX since they are not inﬂuenced by
betrixaban like immunological assays but these do not assess
the activity and have higher turn-around time.
Conclusions and Perspectives
Our results demonstrate an important lack of sensitivity for
routine tests as reported for other DOACs. As it has been
observed with other DOACs, chromogenic anti-Xa assays
seem to be interesting candidates to assess the presence of
low levels of betrixaban, below 120 ng/mL, but adapted
methodologies should be evaluated to improve sensitivity
of these reagents for on-therapy range. However, this study
shows that adapted-chromogenic anti-Xa assays are the
most appropriate assays tomeasure the anti-coagulant effect
of betrixaban. Broadly used coagulation assays such as PT or
aPTT are not appropriate to efﬁciently estimate plasma drug
concentration due to several limitations and a lack of sensi-
tivity. The dRVV-T could be informative in certain circum-
stances due to its good sensitivity and its low LOQ. CAT gives
further information on the coagulation process but its use in
clinical settings is limited. Finally, betrixaban signiﬁcantly
affects several haemostasis diagnostic tests, such as LA or
other thrombophilia testing, and this needs to be taken into
consideration when requesting and interpreting such tests.
Table 2 Summary of recommended assays for the measurement of betrixaban in plasma
Useful for measurement Reliable but
requires
laboratory
experience
Not recommended
Chromogenic
anti-Xa assays
dRVVT TGA PT aPTT TT RT
Sensitivity (ng/mL) 1–72 5–6a Peak: 37–58
mVRI: 17–27
5–36 16–57 Insensitive
Dynamic range of
quantitation (ng/mL)b
4–231 3–231 Peak: 122–231
mVRI: 60–231
11–231 21–231 NA
Repeatability (%) 0.6–3.1 0.8–0.9 3.1–8.9 0.5–1.1 0.4–1.2 NA
Dependence of
reagent
Yes Yes Yes Yes Yes No
Linearity of the
response
Yes but further
investigations
required
No No Yes Yes NA
Abbreviations: aPTT, activated partial thromboplastin time; dRVVT, dilute Russell viper venom time; FDA, Food and Drug Administration; mVRI,
mean velocity rate index; NA, not applicable; PT: pro-thrombin time; RT, reptilase time; TGA, thrombin generation assay; TT, thrombin time.
Note: The on-therapy range of concentration for betrixaban is from  9 ng/mL at Ctrough to  122 ng/mL at Cmax for the 40 and 120 mg once daily
doses, respectively (according to the clinical pharmacology and biopharmaceutics reviews of the Center for Drug Evaluation and Research of the
FDA16).
a5 ng/mL and 6 ng/mL for STA-Staclot-DRVV Screen and Conﬁrm, respectively.
bDynamic range of quantiﬁcation is deﬁned as range covering from the lowest observed limit of quantiﬁcation to the maximal concentration tested.
Thrombosis and Haemostasis
Betrixaban: A Practical Laboratory Guide Siriez et al.
Ta
b
le
3
Su
m
m
ar
y
of
th
e
in
ﬂ
ue
nc
e
of
be
tr
ix
ab
an
on
ha
em
os
ta
si
s
as
sa
ys
C
oa
g
u
la
ti
o
n
as
sa
y
Re
ag
en
t
M
et
h
od
C
oa
g
ul
at
io
n
an
al
ys
er
(m
an
u
fa
ct
u
re
r)
In
fl
u
en
ce
d
(Y
es
/N
o
)
A
va
ila
b
ili
ty
Re
co
m
m
en
d
at
io
ns
Th
ro
m
bi
n
ti
m
e
ST
A
-T
hr
o
m
bi
n
C
hr
o
no
m
et
ri
c
ST
A
-R
Ev
ol
ut
io
n
(D
ia
g
no
st
ic
a
St
ag
o)
N
o
24
/7
–a
ll
la
bo
ra
to
ri
es
/
Re
pt
ila
se
ti
m
e
ST
A
-R
ep
ti
la
se
C
hr
o
no
m
et
ri
c
ST
A
-R
Ev
ol
ut
io
n
(D
ia
g
no
st
ic
a
St
ag
o)
N
o
24
/7
–a
ll
la
bo
ra
to
ri
es
/
Lu
pu
s
an
ti
-c
oa
gu
la
nt
ST
A
-S
ta
cl
ot
D
RV
V
Sc
re
en
C
hr
o
no
m
et
ri
c
ST
A
-R
Ev
ol
ut
io
n
(D
ia
g
no
st
ic
a
St
ag
o)
Ye
s
C
an
be
im
pl
em
en
te
d
on
al
lc
oa
g
ul
om
et
er
s
dR
V
V
-T
te
st
in
g
sh
o
ul
d
be
av
oi
de
d
to
de
te
rm
in
e
LA
ST
A
-S
ta
cl
ot
D
RV
V
C
on
ﬁ
rm
A
nt
i-t
hr
om
bi
n
ST
A
-S
ta
ch
ro
m
AT
III
C
hr
o
m
o
ge
ni
c
th
ro
m
bi
n-
ba
se
d
ST
A
-R
Ev
ol
ut
io
n
(D
ia
g
no
st
ic
a
St
ag
o)
N
o
C
an
be
im
pl
em
en
te
d
on
al
lc
oa
g
ul
om
et
er
s
/
H
em
os
IL
Li
q
ui
d
A
nt
it
hr
om
bi
n
C
hr
o
m
o
ge
ni
c
FX
a-
ba
se
d
A
C
L-
TO
P
(I
ns
tr
um
en
ta
ti
on
La
bo
ra
to
ry
)
N
o
In
tr
in
si
c
cl
ot
ti
ng
fa
ct
or
s
ST
A
-C
.K
.
Pr
es
t
C
hr
o
no
m
et
ri
c
ST
A
-R
M
ax
(D
ia
gn
o
st
ic
a
St
ag
o)
Ye
s
24
/7
–a
ll
la
bo
ra
to
ri
es
A
p
pr
o
pr
ia
te
di
lu
ti
on
s
of
th
e
sa
m
pl
e
ha
ve
to
be
pe
rf
or
m
ed
Ex
tr
in
si
c
cl
ot
ti
ng
fa
ct
or
s
Re
co
m
bi
Pl
as
Ti
n
2G
C
hr
o
no
m
et
ri
c
ST
A
-R
M
ax
(D
ia
gn
o
st
ic
a
St
ag
o)
Ye
s
24
/7
–a
ll
la
bo
ra
to
ri
es
A
p
pr
o
pr
ia
te
di
lu
ti
on
s
of
th
e
sa
m
pl
e
ha
ve
to
be
pe
rf
or
m
ed
.
U
se
of
le
ss
se
ns
it
iv
e
re
ag
en
ts
co
ul
d
be
pr
ef
er
re
d
w
he
n
fe
as
ib
le
(e
.g
.,
D
ad
e
In
no
vi
n
fo
r
ex
tr
in
si
c
pa
th
w
ay
)
Fi
br
in
og
en
C
la
us
s
m
et
ho
d
ST
A
-F
ib
ri
no
ge
n
C
hr
o
no
m
et
ri
c
ST
A
-R
M
ax
(D
ia
gn
o
st
ic
a
St
ag
o)
N
o
24
/7
–a
ll
la
bo
ra
to
ri
es
/
Fi
br
in
og
en
PT
-d
er
iv
ed
Re
co
m
bi
Pl
as
Ti
n
2G
C
hr
o
no
m
et
ri
c
A
C
L-
TO
P
(I
ns
tr
um
en
ta
ti
on
La
bo
ra
to
ry
)
N
o
24
/7
–a
ll
la
bo
ra
to
ri
es
/
Pr
ot
ei
n
S
Pr
ot
ei
n
S
A
ct
iv
it
y
C
hr
o
no
m
et
ri
c
A
C
L-
TO
P
(I
ns
tr
um
en
ta
ti
on
La
bo
ra
to
ry
)
Ye
s
24
/7
–a
ll
la
bo
ra
to
ri
es
N
ot
in
ﬂ
ue
nc
ed
un
ti
l1
0
ng
/m
L.
A
t
hi
gh
er
co
nc
en
tr
at
io
n
(f
ro
m
30
ng
/m
L)
,
an
ov
er
-e
st
im
at
io
n
of
10
%
is
ob
se
rv
ed
.T
hi
s
te
st
sh
ou
ld
be
av
oi
de
d
Pr
ot
ei
n
C
ST
A
-S
ta
ch
ro
m
Pr
ot
ei
n
C
C
hr
o
m
o
ge
ni
c
ST
A
-R
M
ax
(D
ia
gn
o
st
ic
a
St
ag
o)
N
o
24
/7
–a
ll
la
bo
ra
to
ri
es
/
A
ct
iv
at
ed
pr
ot
ei
n
C
re
si
st
an
ce
St
ac
lo
t
A
PC
-R
C
hr
o
no
m
et
ri
c
ST
A
-R
M
ax
(D
ia
gn
o
st
ic
a
St
ag
o)
Ye
s
24
/7
–a
ll
la
bo
ra
to
ri
es
Th
is
te
st
is
sl
ig
ht
ly
in
ﬂ
ue
nc
ed
an
d
ca
n
pr
ov
id
e
fa
ls
e
ne
ga
ti
ve
re
su
lt
s
A
b
br
ev
ia
ti
on
s:
dR
V
V
-T
,
di
lu
te
Ru
ss
el
lv
ip
er
ve
no
m
ti
m
e
LA
,
lu
p
us
an
ti
-c
o
ag
ul
an
t.
Thrombosis and Haemostasis
Betrixaban: A Practical Laboratory Guide Siriez et al.
Conﬂict of Interest
Among the authors, J. Douxﬁls is CEO and founder of
QUALIblood s.a. and reports personal fees from Stago and
Daiichi-Sankyo, outside the submitted work. F. Mullier
reports institutional fees from Stago, Werfen, Nodia,
Sysmex and Bayer. He also reports speaker fees from
Boehringer Ingelheim, Bayer Healthcare and Bristol-
Myers Squibb-Pﬁzer, all outside the submitted work.
Other authors have no conﬂicts of interest to disclose.
Acknowledgments
The authors would like to thank Christelle Vancraeynest,
Philippe Devel, Hélène Haguet and Celine Bouvy for their
contribution to this work. Furthermore, we are grateful
towards Célia Devroye and Maïté Guldenpfenning for
their invaluable assistance.
References
1 Palladino M, Merli G, Thomson L. Evaluation of the oral direct
factor Xa inhibitor - betrixaban. Expert Opin Investig Drugs 2013;
22(11):1465–1472
2 Food and Drug Administration. FDA approved betrixaban (BEV-
YXXA, Portola) for the prophylaxis of venous thromboembolism
(VTE) in adult patients. 2017–06–23. Available at: https://www.
fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/
ucm564422.htm. Accessed July 3, 2017
3 Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared
withwarfarin in patients with atrial ﬁbrillation: results of a phase
2, randomized, dose-ranging study (Explore-Xa). Eur Heart J
2013;34(20):1498–1505
4 Thoenes M, Minguet J, Bramlage K, Bramlage P, Ferrero C. Betrix-
aban - the next direct factor Xa inhibitor? Expert Rev Hematol
2016;9(12):1111–1117
5 Cohen AT, Harrington R, Goldhaber SZ, et al. The design and
rationale for the Acute Medically Ill Venous Thromboembolism
Prevention with Extended Duration Betrixaban (APEX) study. Am
Heart J 2014;167(03):335–341
6 Cohen AT, Harrington RA, Goldhaber SZ, et al; APEX Investigators.
Extended thromboprophylaxis with betrixaban in acutely Ill
medical patients. N Engl J Med 2016;375(06):534–544
7 Chan NC, Bhagirath V, Eikelboom JW. Proﬁle of betrixaban and its
potential in the prevention and treatment of venous thromboem-
bolism. Vasc Health Risk Manag 2015;11:343–351
8 Douxﬁls J, Ageno W, Samama CM, et al. Laboratory testing in
patients treated with direct oral anticoagulants: a practical guide
for clinicians. J Thromb Haemost 2018;16(02):209–219
9 Douxﬁls J, Chatelain B, Chatelain C, Dogné JM, Mullier F. Edoxaban:
impact on routine and speciﬁc coagulation assays. A practical
laboratory guide. Thromb Haemost 2016;115(02):368–381
10 Douxﬁls J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of
apixaban on routine and speciﬁc coagulation assays: a practical
laboratory guide. Thromb Haemost 2013;110(02):283–294
11 Douxﬁls J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM.
Assessment of the impact of rivaroxaban on coagulation assays:
laboratory recommendations for the monitoring of rivaroxaban
and review of the literature. Thromb Res 2012;130(06):956–966
12 Douxﬁls J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM.
Impact of dabigatran on a large panel of routine or speciﬁc
coagulation assays. Laboratory recommendations for monitoring
of dabigatran etexilate. Thromb Haemost 2012;107(05):985–997
13 Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of
low-dose rivaroxaban on speciﬁc coagulation assays and coagula-
tion factor activities in patients under real life conditions. Thromb
Haemost 2013;109(01):127–136
14 Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban
differentially inﬂuences ex vivo global coagulation assays based
on the administration time. Thromb Haemost 2011;106(01):
156–164
15 Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation
parameters in patients receiving dabigatran etexilate or rivarox-
aban: two observational studies in patients undergoing total hip
or total knee replacement. Thromb Res 2011;127(05):457–465
16 Food and Drug Administration. Clinical Pharmacology and Bio-
pharmaceutics review(s); 2016–10–23. Available at: https://
www.accessdata.fda.gov/drugsatfda_docs/nda/2017/
208383Orig1s000ClinPharmR.pdf. Accessed July 3, 2017
17 Camici GG, Steffel J, AkhmedovA, et al. Dimethyl sulfoxide inhibits
tissue factor expression, thrombus formation, and vascular
smooth muscle cell activation: a potential treatment strategy
for drug-eluting stents. Circulation 2006;114(14):1512–1521
18 Practical-Haemostasis.com - A Practical Guide to Laboratory
Haemostasis, Dilute Russell’s Viper Venom Time [DRVVT]. Avail-
able at: http://www.practical-haemostasis.com/Thrombophilia%
20Tests/APS/drvvt.html. Accessed August 7, 2017
19 Douxﬁls J, Gosselin RC. Laboratory assessment of direct oral
anticoagulants. Semin Thromb Hemost 2017;43(03):277–290
20 Kitchens CS. To bleed or not to bleed? Is that the question for the
PTT?. J Thromb Haemost 2005;3(12):2607–2611
21 Gosselin RC, Adcock D, Hawes EM, Francart SJ, Grant RP, Moll S.
Evaluating the use of commercial drug-speciﬁc calibrators for
determining PT and APTT reagent sensitivity to dabigatran and
rivaroxaban. Thromb Haemost 2015;113(01):77–84
22 Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory
measurement of direct factor Xa inhibitors: anti-Xa assay is
preferable to prothrombin time assay. Thromb Haemost 2010;
104(06):1263–1271
23 Hillarp A, Gustafsson KM, Faxälv L, et al. Effects of the oral, direct
factor Xa inhibitor apixaban on routine coagulation assays and
anti-FXa assays. J Thromb Haemost 2014;12(09):1545–1553
24 Moore GW. Recent guidelines and recommendations for labora-
tory detection of lupus anticoagulants. Semin Thromb Hemost
2014;40(02):163–171
25 Exner T, Ellwood L, Rubie J, Barancewicz A. Testing for new oral
anticoagulants with LA-resistant Russells viper venom reagents.
An in vitro study. Thromb Haemost 2013;109(04):762–765
What is known about this topic?
• Therapeutic monitoring is not necessary with betrix-
aban but may be required in some clinical situations.
• No guidance documents are currently available to
guide on the assay to use to perform measurement.
• Other DOACs have shown interferences with routinely
used coagulation assays leading to misdiagnosis.
What does this paper add?
• This study provides a comparison of the impact of
betrixaban on speciﬁc and routinely used coagulation
assays with a large panel of reagents.
• The performance of these tests in terms of sensitivity,
limit of detection, limit of quantitation, dynamic range
of measurement and repeatability were assessed.
• Chromogenic anti-Xa assays with adapted methodol-
ogies are themost recommended assays for the assess-
ment of betrixaban.
Thrombosis and Haemostasis
Betrixaban: A Practical Laboratory Guide Siriez et al.
26 Altman R, Gonzalez CD. Simple and rapid assay for effect of the
new oral anticoagulant (NOAC) rivaroxaban: preliminary results
support further tests with all NOACs. Thromb J 2014;12(01):7
27 Altman R, Gonzalez CD. Supporting the use of a coagulometric
method for rivaroxaban control: a hypothesis-generating study to
deﬁne the safety cut-offs. Thromb J 2015;13:26
28 Testa S, Legnani C, Tripodi A, et al. Poor comparability of coagula-
tion screening test with speciﬁc measurement in patients receiv-
ing direct oral anticoagulants: results from a multicenter/
multiplatform study. J Thromb Haemost 2016;14(11):2194–2201
29 Smith SA, Comp PC, Morrissey JH. Phospholipid composition
controls thromboplastin sensitivity to individual clotting factors.
J Thromb Haemost 2006;4(04):820–827
30 Smith SA, Comp PC, Morrissey JH. Traces of factor VIIa modulate
thromboplastin sensitivity to factors V, VII, X, and prothrombin.
J Thromb Haemost 2006;4(07):1553–1558
31 Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays
to measure the factor Xa-inhibiting properties of apixaban–an
oral, direct and selective factor Xa inhibitor. J Thromb Thrombo-
lysis 2011;32(02):183–187
32 Becker RC, Alexander JH, Newby LK, et al. Effect of apixaban, an
oral and direct factor Xa inhibitor, on coagulation activity bio-
markers following acute coronary syndrome. Thromb Haemost
2010;104(05):976–983
33 Jensen KOF, Hansen SH, Goetze JP, Jesting A, Stensballe J, Hansen H.
Preliminary report: measurement of apixaban and rivaroxaban in
plasma from bleeding patients. Eur J Haematol 2017;99(05):
431–436
34 Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An
optimised, rapid chromogenic assay, speciﬁc for measuring direct
factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost
2010;104(05):1078–1079
35 Lessire S, Douxﬁls J, Pochet L, et al. Estimation of rivaroxaban
plasma concentrations in the perioperative setting in patients
with or without heparin bridging. Clin Appl Thromb Hemost
2018;24(01):129–138
36 Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M.
Determination of rivaroxaban by different factor Xa speciﬁc
chromogenic substrate assays: reduction of interassay variability.
J Thromb Thrombolysis 2011;32(03):267–271
37 Jourdi G, Siguret V, Martin AC, et al. Association rate constants
rationalise the pharmacodynamics of apixaban and rivaroxaban.
Thromb Haemost 2015;114(01):78–86
38 Robert S, Ghiotto J, Pirotte B, et al. Is thrombin generation the new
rapid, reliable and relevant pharmacological tool for the devel-
opment of anticoagulant drugs? Pharmacol Res 2009;59(03):
160–166
39 Gerotziafas GT, Baccouche H, Sassi M, et al. Optimisation
of the assays for the measurement of clotting factor activity
in the presence of rivaroxaban. Thromb Res 2012;129(01):
101–103
40 Ratzinger F, Lang M, Belik S, et al. Lupus-anticoagulant testing at
NOAC trough levels. Thromb Haemost 2016;116(02):235–240
41 Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple
method for removing DOACs from plasma samples. Thromb Res
2018;163:117–122
Thrombosis and Haemostasis
Betrixaban: A Practical Laboratory Guide Siriez et al.
